ClinicalTrials.gg
RecruitingNCT07616141NAET4-SNACCUpdated Nov 3, 2026

Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma

A Phase 2 interventional study of Anlotinib Hydrochloride and Epirubicin in Adenoid Cystic Carcinoma, sponsored by Eye & ENT Hospital of Fudan University. Recruiting at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Eye & ENT Hospital of Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 3, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Carcinoma, Adenoid Cystic with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Carcinoma, Adenoid Cystic · China.

Planned enrollment
3rd of 12
76 · median 40
Started
2026
with 4 others
Phase 2
10 of 14
5 open now
Registered
13th of 14
by date
Lead sponsor
5 of 14
Eye & ENT Hospital of Fudan University

Among the 14 studies in Carcinoma, Adenoid Cystic with a site in China, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 in phase 2, and was the 13th registered.

Carcinoma, Adenoid Cystic

86 studies on the registry are indexed under Carcinoma, Adenoid Cystic; 26 are open to participants now.

Browse Carcinoma, Adenoid Cystic studies →

Open to participants now

7 of the 14 studies in Carcinoma, Adenoid Cystic with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 23 Carcinoma, Adenoid Cystic studies recruiting now, 15 (65%) set no upper age limit and 3 (13%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Adenoid Cystic with a site in China, or all of them as a file.
02

Study summary

T4 stage sinonasal adenoid cystic carcinoma (SNACC) is a rare but aggressive cancer in the nasal cavity and sinuses. These tumors often invade the skull base, eye socket, or brain covering (dura), making complete surgical removal difficult and carrying a high risk of recurrence even after surgery and radiation. The goal of this study is to test whether a new combination of drugs given before surgery - anlotinib (a targeted therapy) plus epirubicin (a chemotherapy drug) - can improve outcomes for patients with T4 SNACC.

This is a prospective, multicenter, single-arm, phase II clinical trial. Eligible participants will receive 2 cycles of neoadjuvant treatment (anlotinib orally for 2 weeks on/1 week off, plus epirubicin intravenously on day 1 of each 3-week cycle). After completing neoadjuvant therapy, participants will undergo surgery to remove the tumor, followed by postoperative radiotherapy. The main question the study tries to answer is whether this approach increases the 3-year progression-free survival (PFS) rate compared to the historical rate of about 70% with standard treatment (surgery plus radiotherapy alone). Secondary questions include how many tumors shrink after neoadjuvant treatment, how many operations achieve complete removal with negative margins, major pathological response rates, overall survival, safety, quality of life, and the chance of avoiding disfiguring surgeries (such as removal of the eye or part of the skull). The study will enroll about 76 participants from 5 top medical centers in China. If positive, this study may establish a new standard of care for T4 SNACC.

Read the detailed description

Sinonasal adenoid cystic carcinoma (SNACC) is a rare cancer. T4 stage tumors often invade the skull base, orbit, or dura, making complete surgical removal difficult. Even with surgery and radiotherapy, the 3-year progression-free survival (PFS) is only about 70%, and extensive resection may cause disfigurement or loss of function.

This is a prospective, multicenter, single-arm, phase II trial. Eligible patients will receive 2 cycles of neoadjuvant therapy (anlotinib 10 mg orally on days 1-14 plus epirubicin 70 mg/m² IV on day 1, 21-day cycle). After neoadjuvant treatment, patients undergo surgery followed by postoperative radiotherapy.

The primary endpoint is 3-year PFS rate, compared with the historical rate of 70%. Secondary endpoints include objective response rate, R0 resection rate, major pathological response, overall survival, safety, quality of life, and organ preservation rate. Exploratory endpoints include biomarkers, ctDNA dynamics, and organoid drug sensitivity.

Target sample size is 76 patients from 5 Chinese centers. The study has been approved by the Institutional Review Board of Eye \& ENT Hospital of Fudan University (approval number 2026069-1). Written informed consent will be obtained from all participants.

03

Conditions studied

  • Adenoid Cystic Carcinoma

Keywords

  • Adenoid Cystic Carcinoma
  • Sinonasal
  • T4 Stage
  • Neoadjuvant Therapy
  • Anlotinib
  • Epirubicin
  • Prospective Study
  • Phase II Clinical Trial
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years, any sex.
  • Histopathologically confirmed sinonasal adenoid cystic carcinoma (any subtype).
  • Stage T4a or T4b according to AJCC 8th edition. If lymph node is present, it must be surgically resectable. If distant metastasis is present, metastatic lesions must be stable.
  • Multidisciplinary team (MDT) assessment confirms that the tumor is technically resectable but with high risk (invasion of skull base, orbit, dura, etc.).
  • (ECOG) performance status 0-1.
  • Adequate bone marrow, liver, kidney, and cardiac function: ≥1.5×10⁹/L, count ≥100×10⁹/L, ≥90 g/L; /AST ≤2.5× (ULN), total ≤1.5×ULN; creatinine ≤1.5×ULN or ≥60 mL/min; (LVEF) ≥50%.
  • Willing to participate and able to provide written (including for clinical treatment and translational research).

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy to the head and neck region.
  • Prior anthracycline therapy with cumulative dose ≥300 mg/m².
  • Known to any component of anlotinib or epirubicin.
  • Uncontrolled hypertension, severe cardiovascular disease, or active infection.
  • Pregnant or breastfeeding women.
  • Any medical or psychosocial condition that, in the investigator's judgment, may interfere with study compliance or conduct.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Anlotinib + Epirubicin

    Participants receive neoadjuvant therapy for 2 cycles (each cycle is 21 days). Anlotinib 10 mg orally once daily on days 1-14 (2 weeks on, 1 week off). Epirubicin 70 mg/m² intravenous infusion on day 1 of each cycle. After completion of neoadjuvant therapy, participants undergo radical surgery followed by postoperative radiotherapy as per protocol.

    Drug: Anlotinib Hydrochloride · Drug: Epirubicin

Interventions

06

What researchers measure

Primary outcomes

  1. 3-Year Progression-Free Survival

    Progression-free survival (PFS) is defined as the time from enrollment to the first documentation of disease progression (local recurrence, regional recurrence, or distant metastasis) or death from any cause, whichever occurs first. The 3-year PFS rate is the proportion of participants who remain alive and free from disease progression at 3 years after enrollment.

    Time frame: From enrollment to 3 years post-enrollment (assessed every 3 months for the first 2 years, then every 6 months) or until progression or death

Secondary outcomes

  1. Objective Response Rate (ORR)

    Proportion of participants achieving complete response (CR) or partial response (PR) after neoadjuvant therapy, assessed by RECIST v1.1 (blinded independent central review).

    Time frame: At week 6 (after completion of 2 cycles of neoadjuvant therapy, before surgery)

  2. R0 Resection Rate

    Proportion of participants undergoing surgery who achieve microscopically negative margins (no tumor cells at the resection margin on final pathology).

    Time frame: At time of surgery (approximately week 10-12 after enrollment)

  3. Overall Survival

    Time from enrollment to death from any cause. Participants who are alive at last follow-up will be censored.

    Time frame: From enrollment up to 5 years (assessed every 3 months for first 2 years, then every 6 months)

  4. Local Control Rate

    Proportion of participants without local recurrence (at primary tumor site) at specified time points.

    Time frame: At 1 year, 2 years, and 3 years post-enrollment

  5. Adverse events

    Incidence, type, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) assessed by CTCAE version 5.0.

    Time frame: From first dose of study drug until 30 days after last dose or surgery, whichever is later

  6. EORTC QLQ-C30

    Change from baseline in EORTC QLQ-C30 physical functioning scale score. The EORTC QLQ-C30 physical functioning scale ranges from 0 to 100, with higher scores indicating better physical functioning.

    Time frame: Baseline, at week 6 (after neoadjuvant therapy), at 6 months, 12 months, 24 months, and 36 months post-enrollment

  7. Organ Preservation Rate

    Proportion of participants who avoid disfiguring surgeries including orbital exenteration, maxillectomy, craniotomy, or skull base resection compared to hypothetical initial surgery without neoadjuvant therapy.

    Time frame: At time of surgery (approximately week 10-12 after enrollment)

07

Study locations

1 of 5 sites recruiting
08

References and documents

Publications

  • Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Meng X, Van Tornout JM, Conlan MG, Kang H. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res. 2023 Nov 14;29(22):4555-4563. doi: 10.1158/1078-0432.CCR-23-1030. PubMed 37643133 ↗
  • Lupinetti AD, Roberts DB, Williams MD, Kupferman ME, Rosenthal DI, Demonte F, El-Naggar A, Weber RS, Hanna EY. Sinonasal adenoid cystic carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2007 Dec 15;110(12):2726-31. doi: 10.1002/cncr.23096. PubMed 17960615 ↗
  • Michel G, Joubert M, Delemazure AS, Espitalier F, Durand N, Malard O. Adenoid cystic carcinoma of the paranasal sinuses: retrospective series and review of the literature. Eur Ann Otorhinolaryngol Head Neck Dis. 2013 Nov;130(5):257-62. doi: 10.1016/j.anorl.2012.09.010. Epub 2013 Jun 6. PubMed 23747147 ↗
  • Song X, Sun J, Yang G, Wang X, Wang L. Long-term outcomes of platinum-based chemotherapy for T4 stage sinonasal adenoid cystic carcinoma. Front Pharmacol. 2025 Sep 29;16:1623242. doi: 10.3389/fphar.2025.1623242. eCollection 2025. PubMed 41089828 ↗
  • Mauthe T, Holzmann D, Soyka MB, Mueller SA, Balermpas P, Held U, Freiberger SN, Rupp NJ, Meerwein CM. Overall and disease-specific survival of sinonasal adenoid cystic carcinoma: a systematic review and meta-analysis. Rhinology. 2023 Dec 1;61(6):508-518. doi: 10.4193/Rhin23.204. PubMed 37703531 ↗
  • Cavalieri S, Mariani L, Vander Poorten V, Van Breda L, Cau MC, Lo Vullo S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Calareso G, Clement P, Hauben E, Platini F, Bossi P, Licitra L, Locati LD. Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. Eur J Cancer. 2020 Sep;136:35-42. doi: 10.1016/j.ejca.2020.05.013. Epub 2020 Jul 3. PubMed 32629365 ↗
  • Seok J, Lee DY, Kim WS, Jeong WJ, Chung EJ, Jung YH, Kwon SK, Kwon TK, Sung MW, Ahn SH. Lung metastasis in adenoid cystic carcinoma of the head and neck. Head Neck. 2019 Nov;41(11):3976-3983. doi: 10.1002/hed.25942. Epub 2019 Aug 29. PubMed 31463986 ↗
  • Mavrikios A, Goudjil F, Beddok A, Zefkili S, Bolle S, Feuvret L, Le Tourneau C, Choussy O, Sauvaget E, Herman P, Dendale R, Calugaru V. Proton therapy and/or helical tomotherapy for locally advanced sinonasal skull base adenoid cystic carcinoma: Focus on experience of the Institut Curie and review of literature. Head Neck. 2023 Jul;45(7):1619-1631. doi: 10.1002/hed.27371. Epub 2023 Apr 25. PubMed 37097003 ↗
  • Bjorndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, Homoe P, Sorensen CH, Andersen E, Bundgaard T, Primdahl H, Lambertsen K, Andersen LJ, Godballe C. Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2011 Jul;47(7):677-82. doi: 10.1016/j.oraloncology.2011.04.020. Epub 2011 May 25. PubMed 21612974 ↗
  • Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol. 2006 Sep;42(8):759-69. doi: 10.1016/j.oraloncology.2006.01.001. Epub 2006 Jun 6. PubMed 16757203 ↗

Individual participant data

Plan to share: No — IPD will not be shared due to concerns about participant privacy and limitations of informed consent.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 28 phase 2 interventional studies under Carcinoma, Adenoid Cystic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 67. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2026
First posted
Jun 1, 2026
StartActual
Jun 1, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2031
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
Show 5 sites
  • Xuanwu Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
  • The Third Affiliated Hospital of Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
  • The Affiliated Hospital of Qingdao University · Qingdao, Chinano status→Not yet recruiting
  • Zhongshan Hospital, Fudan University · Shanghai, Chinano status→Not yet recruiting
  • Eye & ENT Hospital of Fudan University · Shanghai, Chinano status→Recruiting
Nov 3, 2026
Interventions
Added Drug: Anlotinib Hydrochloride·Drug: Epirubicin; removed Drug: Anlotinib + Epirubicin
Nov 3, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionEORTC QLQ-C30: how it is measured was reworded
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Not yet recruiting→Recruiting
    5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
    Show 5 sites
    • Xuanwu Hospital, Capital Medical University · Beijing, Chinano status→Not yet recruiting
    • The Third Affiliated Hospital of Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
    • The Affiliated Hospital of Qingdao University · Qingdao, Chinano status→Not yet recruiting
    • Zhongshan Hospital, Fudan University · Shanghai, Chinano status→Not yet recruiting
    • Eye & ENT Hospital of Fudan University · Shanghai, Chinano status→Recruiting
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionEORTC QLQ-C30: how it is measured was reworded
    Interventions Added Drug: Anlotinib Hydrochloride·Drug: Epirubicin; removed Drug: Anlotinib + Epirubicin
    + 2 other changes: index terms and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07616141
Responsible party
Quan Liu (Principal Investigator, Eye & ENT Hospital of Fudan University) — Principal investigator
First posted
Jun 1, 2026
Start date
Jun 1, 2026
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2031 (estimated)
Last update
Nov 3, 2026

Study contacts

Quan Liu, MD
Contact
liuqent@163.com
+86 15001959681
Wanpeng Li, MD
Contact
18879117831@163.com
+86 13262856870

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Catequentinib hydrochloride · Epirubicin

Start the discussion